CNSX:CLPharmaceuticals
Cresco Labs (CNSX:CL) Quarterly Loss Worsening Challenges Bullish Margin Recovery Narratives
Cresco Labs (CNSX:CL) closed FY 2025 with fourth quarter revenue of US$161.6 million, Basic EPS of a US$0.24 loss, and net income excluding extra items of a US$87.6 million loss. This compares with the prior year’s fourth quarter revenue of US$175.9 million, Basic EPS of a US$0.01 loss, and net income excluding extra items of a US$4.4 million loss. Over the past six reported quarters, the company has seen quarterly revenue range from US$161.6 million to US$179.8 million, while Basic EPS moved...